Search Climate Insights Directory

The report evaluates CCUS as a primary decarbonization lever for India's steel sector, specifically targeting the emission-intensive BF-BOF route. It identifies single-point pre-combustion capture with gas conditioning as the most cost-effective technical approach, with a net CO2 abatement cost of USD 5560/tCO2. The study maps seven steel clusters in Eastern India and finds significant geological storage potential, primarily in deep saline aquifers (estimated at 62 Gt). To overcome high capital costs, the report proposes novel financing instruments like Partial Deep Discount Carbon STRIPS (PDDCS) bonds and the establishment of a Carbon Capture Finance Corporation (CCFC). It concludes that a breakeven carbon price of approximately INR 2,099 (USD 25)/tCO2 is necessary for project financial viability in a mature market.

The report highlights a critical lack of transparency in the antibiotic supply chain for the French market, noting that while formulation often occurs in Europe, active pharmaceutical ingredients (APIs) are primarily sourced from India and China. It documents severe environmental pollution and the proliferation of antibiotic-resistant bacteria around production sites in these countries, linking specific manufacturers like Aurobindo and Mylan to these impacts. The document argues that current French public procurement processes fail to account for these environmental risks and calls for a global audit and stricter transparency requirements to combat antimicrobial resistance.

The document examines how the pharmaceutical industry contributes to the global rise of 'superbugs' through the discharge of antibiotic-laden waste into the environment, particularly in China and India. It highlights a critical lack of transparency in the supply chain and argues that current Good Manufacturing Practices (GMP) fail to include environmental criteria. The report provides case studies of specific companies—such as NCPC, CSPC, and Aurobindo—linked to environmental violations and calls on German health authorities (BfArM) and procurement bodies (BVBG) to integrate environmental and AMR criteria into their licensing and purchasing processes to prevent the further spread of drug-resistant bacteria.

The report documents severe water and soil contamination caused by the bulk drug industry in India, particularly in Telangana and Andhra Pradesh. It highlights a systemic failure of waste treatment infrastructure and regulatory oversight, linking local pollution to the global spread of antimicrobial resistance (AMR). The investigation identifies major pharmaceutical companies, including Aurobindo, Dr Reddy's, Hetero, and Mylan, as significant polluters whose products enter global markets, while local communities suffer from chronic health issues and destroyed livelihoods.

The report documents systematic pharmaceutical pollution in India, particularly in the bulk drug manufacturing hubs of Hyderabad and Visakhapatnam. It argues that the discharge of active pharmaceutical ingredients (APIs) into waterways contributes to the global threat of antimicrobial resistance (AMR) and causes severe local health and environmental degradation. The document highlights a failure of regulatory oversight and a lack of supply chain transparency, which allows multinational pharmaceutical companies to outsource production to polluting sites without accountability. It recommends integrating environmental standards into the Good Manufacturing Practice (GMP) framework and increasing transparency in supplier relationships.

The document discusses the tension between aesthetic and functional choices in urban greening across Indian cities, noting that many commonly planted exotic species are prone to uprooting during extreme weather events like cyclones. It highlights a lack of scientific rigour in national guidelines and fragmented institutional management of urban greenery, while weighing the biodiversity benefits of native species against the perceived hardiness of non-native species in urban environments.